Baseline characteristics of patients with COPD treated with Budesonide / Glycopyrronium / Formoterol in the real world; The RECORD Study

被引：0
|
作者：
Watz, Henrik [1 ]
Halbach, Marija [2 ]
Saathoff, Matthias [2 ]
Morris, Tamsin [3 ]
Watt, Michael
Singh, Dave [4 ,5 ]
机构：
[1] LungenClin Grosshansdorf, Pneumol Forschungsinst, Grosshansdorf, Germany
[2] AstraZeneca GmbH, AstraZeneca Deutschland, Hamburg, Germany
[3] AstraZeneca GmbH, Astrazeneca UK, London, England
[4] AstraZeneca GmbH, Astrazeneca UK, London, England
[5] Univ Manchester, Div Infect Immun Resp Med, Manchester, Lancs, England
来源：
INNERE MEDIZIN | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P11-02
引用
收藏
页码：S79 / S79
页数：1
相关论文
共 50 条
  • [1] Baseline characteristics of patients with COPD treated with Budesonide/Glycopyrronium/ Formoterol in the real world; the RECORD study
    Watz, H.
    Halbach, M.
    Saathoff, M.
    Morris, T.
    Watt, M.
    Singh, D.
    PNEUMOLOGIE, 2024, 78 : S64 - S64
  • [2] Budesonide/Glycopyrronium/Formoterol in the real world; The RECORD Study
    Watz, Henrik
    Halbach, Marija
    Saathoff, Matthias
    Morris, Tamsin
    Watt, Michael
    Milano, Annika Fernandez
    Shrikrishna, Dinesh
    Singh, Dave
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [3] Real-world outcomes of Budesonide/Glycopyrronium/Formoterol therapy in COPD after 3 months; Interim analysis of the RECORD study
    Watz, Henrik
    Halbach, Marija
    Saathoff, Matthias
    Morris, Tamsin
    Watt, Michael
    Milano, Annika Fernandez
    Shrikrishna, Dinesh
    Singh, Dave
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [4] Budesonide/Glycopyrronium/Formoterol: A Review in COPD
    Heo, Young-A
    DRUGS, 2021, 81 (12) : 1411 - 1422
  • [5] Budesonide/Glycopyrronium/Formoterol: A Review in COPD
    Young-A Heo
    Drugs, 2021, 81 : 1411 - 1422
  • [6] Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
    Young-A Heo
    Drugs, 2021, 81 : 1699 - 1699
  • [7] Real-world study of formoterol/budesonide delivered through BAI in COPD patients
    Balamurugan, Santhalingam
    Pophale, Himanshu
    Samariya, Utsav
    Apte, Komalkirti
    Singh, Sheetu
    Dhar, Raja
    Rajan, Sujeet
    Swarnakar, Rajesh
    Talwar, Deepak
    Lopez, Meena
    Naik, Vaishali
    Sawant, Sandesh
    Chhowala, Sushmeeta
    Vaidya, Abhijit
    Gogtay, Jaideep
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [8] First Real-World Evidence on budesonide/glycopyrronium/formoterol fumarate (BGF) use for COPD patients in France (ENARXI study): an interim analysis
    Deslee, Gaetan
    Poccardi, Nolwenn
    Fabry-Vendrand, Caroline
    Leynaud, Delphine
    Thabut, Gabriel
    Eteve-Pitsaer, Caroline
    Coriat, Adrien
    Ghout, Idir
    Leleu, Henri
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [9] Characteristics of Patients with COPD Initiating Budesonide/Glycopyrronium/Formoterol or Other Triple Therapies in Japan: A Real-World Healthcare Claims Database Study (MITOS-AURA)
    Takahashi, Koichiro
    Makita, Naoyuki
    Castaneda-Sanabria, Johann
    Argoubi, Ramzi
    Nowacki, Gregoire
    Issa, Seham
    Matsumoto, Isao
    Yoshida, Yuri
    Mullerova, Hana
    ADVANCES IN THERAPY, 2024, 41 (12) : 4518 - 4536
  • [10] Characteristics of COPD patients initiating budesonide/glycopyrronium/formoterol (BGF) and other triple therapy in Japan: a health-care claims-based real-world database study (MITOS program)
    Takahashi, Koichiro
    Makita, Naoyuki
    Castaneda, Johann
    Argoubi, Ramzi
    Nowacki, Gregoire
    Issa, Seham
    Matsumoto, Isao
    Yoshida, Yuri
    Mullerova, Hana
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
12345